• AFRIMS to install Airocide® technology to protect visitors and staff
  • AFRIMS is a biomedical research facility of the U.S. Army’s Walter Reed Army Institute of Research

MOUNT VERNON, NY / ACCESSWIRE / December 1, 2021 / Applied UV, Inc. (NASDAQ:AUVI) (“Applied UV” or the “Company”), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light (“UVC”) for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that its exclusive distribution partner in Thailandwill be installing Airocide® units at the Armed Forces Research Institute of Medical Sciences (“AFRIMS”), Bangkok, Thailand, to help create safer and cleaner environments for visitors and staff. AFRIMS is a biomedical research facility of the U.S. Army’s Walter Reed Army Institute of Research (“WRAIR”). AFRIMS, with a mission that has resulted in ground-breaking research in military medicine across nations in Southeast Asia and the Indian Subcontinent, has primarily focused on diseases related to infectious pathogens.

AFRIMS has a dual Royal Thai Army and US Army Command with the American Component being a special foreign activity of the WRAIR in Washington, DC. Since 1893, the WRAIR has been a leader in solving significant threats to Soldier readiness and lethality such as disease and battle injury. WRAIR’s broad research capabilities at its Washington, D.C., area and expeditionary laboratories function in concert to afford Soldiers the best medical protection and support possible before, during, and after deployment by addressing both longstanding and emerging threats. Though WRAIR’s research is focused on Soldier health, its products have important civilian applications, saving countless lives around the world.

With the ongoing fight against COVID-19 and the recent global emergence of the new Omicron strain, AFRIMS is installing Airocide® systems to control airborne diseases and protect critical areas within the facility. The installation of the Airocide GCS series units at the research facility demonstrates the commitment of Thailand’s medical community to seek out and provide the best in air purification and sanitizing technology by which to protect their employees.

Armed with one of the only known, FDA Listed Class II Medical Devices that has been clinically proven to kill COVID 19, Applied UV continues to enhance its distributor relationships throughout Southeast Asia and around the world to meet the demand for its air and surface infection control products. The installation at this leading military research facility coupled with other global installations (JetBlue Park, Boston Red Sox, US Army Aberdeen Proving Grounds, Bangkok Metropolitan Administration Lat Krabang Hospital, Palace of Versailles) further demonstrates the efficacy and safety of the patented Airocide air purification platform by having these institutions trust the protection of their staffs, consumers and facilities with our product.

“The installation of our Airocide® units at such a prestigious biomedical facility represents another significant milestone in our strategy to significantly grow our international commercial distribution capabilities and enter new markets,” said Max Munn, Founder and President of Applied UV. “Our Thailand distributor, Sithiporn Associates, is one of the leading scientific equipment distributors in Thailand and ASEAN region and have been excellent partners to commercialize our innovative and clinically proven portfolio of pathogen eliminating technology. Hospitals and research facilities are increasingly recognizing the benefits of installing Airocide® systems in communal spaces to interrupt the transmission of airborne infectious agents and destroy those microbes rapidly while keeping the occupants safe from any harmful byproducts.”

Airocide® utilizes NASA optimized photocatalytic oxidation (“PCO”) technology wherein air and any contaminants are drawn from the room into the Airocide® unit and channeled into the reaction chamber. UVC activates the proprietary photocatalyst embedded in the reaction chamber, beginning the photocatalytic process. In the reaction chamber, hydroxyl radicals and super-oxide ions are generated and oxidize every organic molecule that comes in contact. The reaction bed is designed to allow the surface-bound radicals nearly three hundred and sixty degrees of exposure for maximum likelihood of collisions with pathogens and other organic material. Millions of hydroxyl radicals converge, combining with the carbon atoms in pathogens (airborne bacteria, mold, fungi, mycotoxins, viruses, allergens) and VOCs, converting the organic material into a harmless vapor and clean, clear air.

Airocide System

The Airocide® System, originally developed for NASA with assistance from the University of Wisconsin at Madison, is an airborne pathogen killing technology that uses a patented combination of UVC and a proprietary, titanium dioxide based photocatalyst. Listed as an FDA Class II Medical device, the Airocide® technology is clinically proven and field tested to kill/remove/eliminate airborne pathogenic and non-pathogenic microorganisms, allergens, odors and harmful VOCs in a variety of applications and industries including healthcare, hospitality, grocery chains, wineries, commercial real estate, schools, dental offices and homes. Airocide® air purifiers are available at www.airocide.com

About Applied UV

Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries – SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections (“HAIs”). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company’s Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices’ proximity. The Company’s patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen’s Airocide® products for air purification, developed for NASA and FDA Cleared as class II medical devices, utilize a proprietary photo-catalytic bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous pathogens, destructive VOCs and biological gasses into harmless water vapor without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, and homes.

For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/https://sterilumen.com/; and, https://munnworks.com/.

Forward-Looking Statements

The information contained herein may contain “forward‐looking statements.” Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company’s current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company’s actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.


Applied UV Investor Relations
Kevin McGrath
TraDigital IR

SOURCE: Applied UV, Inc.